Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?

Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of thr...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis journal 2020-08, Vol.18 (1), p.1-15, Article 15
Main Authors: Giffard-Quillon, Lorine, Desmurs-Clavel, Helene, Grange, Claire, Jourdy, Yohann, Dargaud, Yesim
Format: Article
Language:English
Subjects:
Anticoagulants
Apixaban
Drug dosages
Laboratories
Letter to the Editor
Menstruation
Patients
Plasma
Protein binding
Prothrombin
Rivaroxaban
Thrombin
Thromboembolism
Thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of three 4-factor PCCs for reversing rivaroxaban anticoagulant effect. Our in vitro finding indicates that 4-factor PCCs at the dose of 25 U.kg − 1 may be sufficient to reverse rivaroxaban anticoagulant effect.
ISSN:1477-9560
1477-9560
DOI:10.1186/s12959-020-00228-9